LS Investment Advisors LLC Purchases 570 Shares of Kenvue Inc. (NYSE:KVUE)

LS Investment Advisors LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 51,745 shares of the company’s stock after acquiring an additional 570 shares during the quarter. LS Investment Advisors LLC’s holdings in Kenvue were worth $1,197,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. JB Capital LLC grew its holdings in shares of Kenvue by 2.9% during the third quarter. JB Capital LLC now owns 117,301 shares of the company’s stock worth $2,713,000 after purchasing an additional 3,320 shares during the last quarter. Deseret Mutual Benefit Administrators grew its holdings in Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after acquiring an additional 651 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Kenvue by 3.2% during the third quarter. Principal Financial Group Inc. now owns 2,364,451 shares of the company’s stock valued at $54,690,000 after acquiring an additional 73,542 shares during the last quarter. Graypoint LLC bought a new position in shares of Kenvue during the third quarter valued at $233,000. Finally, Blake Schutter Theil Wealth Advisors LLC bought a new stake in shares of Kenvue in the third quarter worth $370,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $22.97 on Friday. Kenvue Inc. has a one year low of $17.67 and a one year high of $23.57. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The firm has a 50-day moving average of $22.61 and a 200-day moving average of $20.50. The company has a market cap of $43.99 billion, a P/E ratio of 39.60, a P/E/G ratio of 3.01 and a beta of 1.36.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The business had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter last year, the company posted $0.32 earnings per share. The firm’s quarterly revenue was down .3% compared to the same quarter last year. Equities research analysts forecast that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.57%. Kenvue’s dividend payout ratio is presently 141.38%.

Analysts Set New Price Targets

KVUE has been the topic of a number of analyst reports. Piper Sandler upped their price target on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. JPMorgan Chase & Co. increased their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Finally, UBS Group upped their target price on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.